GlycoMimetics, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Gaithersburg MD United States (2003)

Organization Overview

First Clinical Trial
2009
NCT00911495
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

GlycoMimetics Incorporated

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 2)

Breast Neoplasms (Phase 1)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Thrombosis (Phase 2)

Venous Thrombosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 11